Code of Federal Regulations: Containing a Codification of Documents of General Applicability and Future Effect as of December 31, 1948, with Ancillaries and IndexDivision of the Federal Register, the National Archives, 1998 Special edition of the Federal Register, containing a codification of documents of general applicability and future effect ... with ancillaries. |
No grāmatas satura
6.–10. rezultāts no 99.
358. lappuse
... less than 30 minutes or by any other suitable method . ( 4 ) Pyrogen - free sodium chloride . Heat sodium chloride for not less than 2 hours at 200 ° C. ( 5 ) Pyrogen - free sodium carbonate . Heat anhydrous sodium carbonate for not ...
... less than 30 minutes or by any other suitable method . ( 4 ) Pyrogen - free sodium chloride . Heat sodium chloride for not less than 2 hours at 200 ° C. ( 5 ) Pyrogen - free sodium carbonate . Heat anhydrous sodium carbonate for not ...
376. lappuse
... less for 3 hours . ( d ) Method 4. Proceed as directed in paragraph ( a ) of this section , except dry the sample at a temperature of 40 ° C. and a pressure of 5 millimeters of mercury or less for 2 hours . ( e ) Method 5. Proceed as ...
... less for 3 hours . ( d ) Method 4. Proceed as directed in paragraph ( a ) of this section , except dry the sample at a temperature of 40 ° C. and a pressure of 5 millimeters of mercury or less for 2 hours . ( e ) Method 5. Proceed as ...
463. lappuse
... less than 85 percent of that which it is represented to contain . ( c ) Procaine penicillin . The procaine penicillin content of the batch is the difference between the total potency determined by the method described in paragraph ( a ) ...
... less than 85 percent of that which it is represented to contain . ( c ) Procaine penicillin . The procaine penicillin content of the batch is the difference between the total potency determined by the method described in paragraph ( a ) ...
467. lappuse
... less than 85 percent of the number of units per milliliter or per gram that it is rep- resented to contain . ( 2 ) Streptomycin content . Proceed as directed in §544.373 ( b ) ( 1 ) ( 1 ) of this chap- ter , except inactivate the ...
... less than 85 percent of the number of units per milliliter or per gram that it is rep- resented to contain . ( 2 ) Streptomycin content . Proceed as directed in §544.373 ( b ) ( 1 ) ( 1 ) of this chap- ter , except inactivate the ...
468. lappuse
... less than 85 per- cent of the number of units that it is represented to contain . ( 2 ) Streptomycin content . Using an ali- quot of the buffer solution prepared as directed in paragraph ( a ) ( 1 ) of this sec- tion , proceed as ...
... less than 85 per- cent of the number of units that it is represented to contain . ( 2 ) Streptomycin content . Using an ali- quot of the buffer solution prepared as directed in paragraph ( a ) ( 1 ) of this sec- tion , proceed as ...
Saturs
279 | |
285 | |
290 | |
299 | |
310 | |
331 | |
339 | |
340 | |
223 | |
236 | |
238 | |
239 | |
240 | |
256 | |
257 | |
262 | |
263 | |
265 | |
270 | |
275 | |
351 | |
483 | |
588 | |
593 | |
696 | |
699 | |
761 | |
826 | |
865 | |
890 | |
911 | |
949 | |
Citi izdevumi - Skatīt visu
Bieži izmantoti vārdi un frāzes
abbre abbreviated application abbreviated new drug acid active ingredient adverse drug experience agency amended antibiotic application or abbreviated bacitracin bioavailability bioequivalence cation Center for Drug certification chapter clinical hold clinical investigation conducted control number copy Cosmetic Act digoxin dosage form dose Drug Administration drug application Drug Evaluation drug prod drug product Drug products containing drug substance Evaluation and Research Federal Food Food and Drug graph gredients hearing hydrochloride identified information requirements ap insulin intended inves investigational new drug labeling manufacturer marketing meet ment milligrams milliliters misbranded neomycin notice oral dosage orphan drug OTC drug product package paragraph percent person plication polymyxin proposed protocol recognized as safe reference listed drug request safe and effective safety section 502 Sodium sponsor statement submission Subpart sulfate tained tigational tion tive treatment treatment IND vestigational viated warning